HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


2017 In Review: FDA's Cosmetics Slowdown Could Bolster Case For Legislative Jumpstart

This article was originally published in The Rose Sheet

Executive Summary

FDA's cosmetics activities fell off noticeably compared with 2016, and the change in the White House spurred the agency to begin looking for regulatory burdens to eliminate while shuffling priorities away from cosmetics to make do with proposed cuts in federal funding. In this climate, robust cosmetics oversight may depend on a legislative update, with multiple draft bills on the table.

You may also be interested in...

FDA Streamlining Voluntary Cosmetic Registration, With Participation On The Rise

New accounts are up 156% from 2014 in FDA’s Voluntary Cosmetic Registration Program, according to FDA, which has made improvements to streamline the submission process for participants and lighten the load on agency staffers. Further changes recommended by industry are currently under consideration.

Claire's Scare Revives Concerns About Asbestos-Tainted Kids' Cosmetics

Another retailer of cosmetics aimed at girls, Claire's, faces allegations of asbestos-contaminated makeup products, less than six months after tweens-focused Justice came under similar fire. Both retailers say their own independent testing showed products in question to be asbestos-free, but the PR damage may be done.

2017 In Review: Plaintiffs Find New Angles For Attacking Cosmetics' Authenticity

Rose Sheet's coverage of consumer litigation targeting personal-care companies for deceptive claims, among other alleged violations, yielded some of its most-read stories in 2017, based on online analytics. Trends are likely to carry over and, in some cases, pick up steam in 2018.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts